DORCHESTER WEALTH MANAGEMENT Co Boosts Holdings in Pfizer Inc. (NYSE:PFE)

DORCHESTER WEALTH MANAGEMENT Co raised its holdings in shares of Pfizer Inc. (NYSE:PFEFree Report) by 3.1% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 241,092 shares of the biopharmaceutical company’s stock after acquiring an additional 7,305 shares during the quarter. Pfizer makes up 1.2% of DORCHESTER WEALTH MANAGEMENT Co’s investment portfolio, making the stock its 29th largest position. DORCHESTER WEALTH MANAGEMENT Co’s holdings in Pfizer were worth $6,941,000 as of its most recent SEC filing.

Several other hedge funds have also recently added to or reduced their stakes in the business. RB Capital Management LLC boosted its holdings in shares of Pfizer by 6.7% during the first quarter. RB Capital Management LLC now owns 5,446 shares of the biopharmaceutical company’s stock valued at $282,000 after acquiring an additional 341 shares during the period. Ironwood Wealth Management LLC. lifted its holdings in Pfizer by 1.1% in the first quarter. Ironwood Wealth Management LLC. now owns 36,081 shares of the biopharmaceutical company’s stock worth $1,868,000 after purchasing an additional 400 shares during the period. United Bank lifted its holdings in Pfizer by 0.6% in the first quarter. United Bank now owns 46,671 shares of the biopharmaceutical company’s stock worth $2,416,000 after purchasing an additional 290 shares during the period. Ergoteles LLC lifted its holdings in Pfizer by 136.3% in the first quarter. Ergoteles LLC now owns 36,766 shares of the biopharmaceutical company’s stock worth $1,903,000 after purchasing an additional 21,209 shares during the period. Finally, Mackenzie Financial Corp lifted its holdings in Pfizer by 6.4% in the first quarter. Mackenzie Financial Corp now owns 1,337,418 shares of the biopharmaceutical company’s stock worth $69,238,000 after purchasing an additional 79,887 shares during the period. 68.36% of the stock is currently owned by hedge funds and other institutional investors.

Pfizer Stock Down 0.5 %

Shares of PFE stock traded down $0.15 during trading hours on Wednesday, reaching $27.40. The company had a trading volume of 11,148,622 shares, compared to its average volume of 42,872,313. The company has a market cap of $155.15 billion, a price-to-earnings ratio of 76.03, a price-to-earnings-growth ratio of 1.24 and a beta of 0.61. The business has a fifty day simple moving average of $27.41 and a 200-day simple moving average of $29.25. The company has a debt-to-equity ratio of 0.69, a current ratio of 0.91 and a quick ratio of 0.69. Pfizer Inc. has a 12 month low of $25.61 and a 12 month high of $42.22.

Pfizer (NYSE:PFEGet Free Report) last posted its quarterly earnings results on Tuesday, January 30th. The biopharmaceutical company reported $0.10 earnings per share for the quarter, topping the consensus estimate of ($0.19) by $0.29. The company had revenue of $14.25 billion for the quarter, compared to the consensus estimate of $14.37 billion. Pfizer had a return on equity of 10.88% and a net margin of 3.62%. The firm’s quarterly revenue was down 41.3% compared to the same quarter last year. During the same quarter in the prior year, the business posted $1.14 EPS. On average, research analysts expect that Pfizer Inc. will post 2.22 earnings per share for the current fiscal year.

Analyst Ratings Changes

PFE has been the topic of several research reports. Barclays dropped their price target on shares of Pfizer from $34.00 to $28.00 and set an “equal weight” rating on the stock in a research report on Thursday, December 14th. TD Cowen downgraded Pfizer from an “outperform” rating to a “market perform” rating and set a $32.00 price objective on the stock. in a report on Thursday, January 4th. Argus downgraded shares of Pfizer from a “buy” rating to a “hold” rating in a research note on Friday, March 22nd. Guggenheim started coverage on Pfizer in a research report on Friday, February 23rd. They issued a “buy” rating and a $36.00 target price for the company. Finally, Truist Financial cut their price objective on Pfizer from $42.00 to $36.00 and set a “buy” rating for the company in a report on Thursday, December 14th. Twelve investment analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and an average price target of $36.88.

Get Our Latest Analysis on PFE

Pfizer Profile

(Free Report)

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

Further Reading

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.